Lebrikizumab shows clear skin and rapid itch‑pain relief in phase 3b hand‑foot eczema trial
Eli Lilly’s IL‑13 inhibitor lebrikizumab (Ebglyss) met its primary endpoint in the phase 3b ADtouch study of moderate‑to‑severe hand and foot atopic dermatitis. At week 16, 53% of patients achieved clear or almost clear skin versus 27% on placebo, with significant itch relief as early as week 2 and pain improvement by week 16. Safety was consistent with the known profile and no new signals emerged. The data were presented at the European Academy of Dermatology and Venereology Congress 2026.
Why it matters
The company indicated the results could support regulatory filing for this indication, potentially adding a new revenue stream for LLY. Analysts note that a successful label expansion may lift future sales forecasts for lebrikizumab.
Key facts
- 1The ADtouch trial enrolled 221 patients with moderate‑to‑severe hand and foot atopic dermatitis. hcplive.com
- 2Patients received lebrikizumab 250 mg every 2 weeks for 16 weeks. hcplive.com
- 353% of lebrikizumab‑treated patients achieved clear or almost clear skin (HF‑IGA 0/1) at week 16 versus 27% on placebo. hcplive.com
- 4Itch improvement of ≥4 points occurred in 57% of lebrikizumab patients versus 19% of placebo patients at week 16. hcplive.com
- 5Pain improvement of ≥4 points occurred in 59% of lebrikizumab patients versus 19% of placebo patients at week 16. hcplive.com
- 6Adverse events were reported in 41.8% of lebrikizumab patients and 39.6% of placebo patients; no new safety signals were identified. healio.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.